guest ::
| Home > Publications database > 11th Immunotherapy of Cancer conference (ITOC): A meeting report. > print |
| Home > Publications database > 11th Immunotherapy of Cancer conference (ITOC): A meeting report. > print |
| 001 | 303012 | ||
| 005 | 20250722114135.0 | ||
| 024 | 7 | _ | |a 10.1080/21645515.2025.2532967 |2 doi |
| 024 | 7 | _ | |a pmid:40679247 |2 pmid |
| 024 | 7 | _ | |a 2164-5515 |2 ISSN |
| 024 | 7 | _ | |a 1554-8600 |2 ISSN |
| 024 | 7 | _ | |a 1554-8619 |2 ISSN |
| 024 | 7 | _ | |a 2164-554X |2 ISSN |
| 037 | _ | _ | |a DKFZ-2025-01459 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Michaelides, Stefanos |0 0000-0002-9001-0207 |b 0 |
| 245 | _ | _ | |a 11th Immunotherapy of Cancer conference (ITOC): A meeting report. |
| 260 | _ | _ | |a Austin, Tex. |c 2025 |b Landes Bioscience |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1753107761_5170 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a The Immunotherapy of Cancer (ITOC) meeting is an international conference providing a platform for immuno-oncologists worldwide to present and discuss their research and newest findings. Being held in Munich annually, the 11th edition took place in April 2025 and saw broad discussions about new concepts in the field of immuno-oncology, mixed with exciting clinical results but also with a glimpse back into the past. This was mirrored by the lifetime achievement award, given to Robert D. Schreiber for his groundbreaking work on the immune surveillance of cancer. ITOC11 impressively showcase how far immuno-oncology has come in a conference extending from the discipline's very beginnings up to some of the most exciting new findings in the field of cancer immunology. The conference has demonstrated that tumor immunology is not only about cancer and immune cells, but extends far beyond. |
| 536 | _ | _ | |a 899 - ohne Topic (POF4-899) |0 G:(DE-HGF)POF4-899 |c POF4-899 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de |
| 650 | _ | 7 | |a CAR T cell therapy |2 Other |
| 650 | _ | 7 | |a ITOC |2 Other |
| 650 | _ | 7 | |a Immunotherapy of Cancer |2 Other |
| 650 | _ | 7 | |a antibody therapy |2 Other |
| 650 | _ | 7 | |a cellular therapy |2 Other |
| 650 | _ | 7 | |a combination therapy |2 Other |
| 650 | _ | 7 | |a tumor immunology |2 Other |
| 650 | _ | 7 | |a tumor vaccination |2 Other |
| 650 | _ | 7 | |a Cancer Vaccines |2 NLM Chemicals |
| 650 | _ | 2 | |a Humans |2 MeSH |
| 650 | _ | 2 | |a Neoplasms: therapy |2 MeSH |
| 650 | _ | 2 | |a Neoplasms: immunology |2 MeSH |
| 650 | _ | 2 | |a Immunotherapy: methods |2 MeSH |
| 650 | _ | 2 | |a Congresses as Topic |2 MeSH |
| 650 | _ | 2 | |a Cancer Vaccines: immunology |2 MeSH |
| 700 | 1 | _ | |a Hartmann, Viktoria |b 1 |
| 700 | 1 | _ | |a Nüssler, Volkmar |b 2 |
| 700 | 1 | _ | |a Zielinski, Christoph |b 3 |
| 700 | 1 | _ | |a von Bergwelt-Baildon, Michael |0 P:(DE-HGF)0 |b 4 |
| 700 | 1 | _ | |a Kobold, Sebastian |0 P:(DE-HGF)0 |b 5 |
| 773 | _ | _ | |a 10.1080/21645515.2025.2532967 |g Vol. 21, no. 1, p. 2532967 |0 PERI:(DE-600)2664177-X |n 1 |p 2532967 |t Human vaccines & immunotherapeutics |v 21 |y 2025 |x 2164-5515 |
| 909 | C | O | |o oai:inrepo02.dkfz.de:303012 |p VDB |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 4 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 5 |6 P:(DE-HGF)0 |
| 913 | 1 | _ | |a DE-HGF |b Programmungebundene Forschung |l ohne Programm |1 G:(DE-HGF)POF4-890 |0 G:(DE-HGF)POF4-899 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-800 |4 G:(DE-HGF)POF |v ohne Topic |x 0 |
| 914 | 1 | _ | |y 2025 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2024-12-18 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2024-12-18 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b HUM VACC IMMUNOTHER : 2022 |d 2024-12-18 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0501 |2 StatID |b DOAJ Seal |d 2024-08-08T20:20:27Z |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0500 |2 StatID |b DOAJ |d 2024-08-08T20:20:27Z |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b DOAJ : Anonymous peer review |d 2024-08-08T20:20:27Z |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2024-12-18 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2024-12-18 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2024-12-18 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1190 |2 StatID |b Biological Abstracts |d 2024-12-18 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2024-12-18 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2024-12-18 |
| 915 | _ | _ | |a IF < 5 |0 StatID:(DE-HGF)9900 |2 StatID |d 2024-12-18 |
| 915 | _ | _ | |a Article Processing Charges |0 StatID:(DE-HGF)0561 |2 StatID |d 2024-12-18 |
| 915 | _ | _ | |a Fees |0 StatID:(DE-HGF)0700 |2 StatID |d 2024-12-18 |
| 920 | 1 | _ | |0 I:(DE-He78)MU01-20160331 |k MU01 |l DKTK Koordinierungsstelle München |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)MU01-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|